Cancer Clinical Trials
Find a clinical trial, talk with your doctor to learn if you are eligible.
*List last updated, July 2021.
|Cancer Type||Trial Name||Site|
||OTS1070103:A Phase I Study of OTS167PO,a MELK inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast cancer||Norwalk|
|SGNLVA-001:A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer||Norwalk|
|SGNLVA-002: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer||Norwalk|
|WO41544: A PhaseIII, Randomized, Double-blind,Placebo-controlled Study evaluating The efficacy and safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients with Metastatic Breast Cancer.PIK3CA-Mutant, Hormone receptor positive, Her2-Negative Locally Advanced or or Metastatic Breast Cancer.||Norwalk|
|A011202:A Randomized, Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy||Norwalk / VBMC|
|S1418/BR006: A Randomized Phase III Trial to Evaluate Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/=1 CM Residual Invasive Cancer or Positive Lymph Nodes (>ypN+) After Neoadjuvant Chemotherapy||Norwalk/Danbury|
|ARV-471-mBC-101: A Phase 1/2, open label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting||Norwalk|
|18-002: A Phase I Study of Rucaparib Administered Concurrently with Postoperative Radiotherapy in Patients with Triple Negative Breast Cancer with an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy||Norwalk|
|18-109: A Feasibility Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromotase Inhibitors||Norwalk|
|19-401: Triple Negative Breast Cancer Clinic Program at Norwalk Hospital||Norwalk|
|19-300: Ultra-Short External Beam-Based Accelerated Partial Breast irradiation (APBI) : A phase II Toxicity Study Nested with a Non- inferiority Assessment of APBI in New Patient Cohorts||Norwalk|
|BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer||Norwalk/Danbury|
|NSABP-B-59/GBG 96-GeparDouze: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo.||VBMC|
|A011801: The COMPASSHER2 Trials ( COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatnib.
|A191901:Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
|Breast & Lung||18-486 PROMISE-005: A Phase II Randomized Study Assessing the Efficacy of Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic Breast or Lung Cancer||Norwalk|
|Bladder||A031501 PHASE III Randomized Adjuvant study of MK-3475 (pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (ambassador) versus observation
|Lung||A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
|E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
|ELCAP: International Early Lung Cancer Action Program||VBMC|
|Thoracic Surgery||IELCART: Initiative for Early Lung Cancer Research on Treatment||VBMC|
|PLOTS: Intraoperative, Percutaneous Localization of Peripheral Pulmonary Nodules for Resection: A Prospective, Open-Label, Multi-Center Registry Study of Thoracic Surgery Outcomes||VBMC|
||NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
|NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
|NRG-GY020: “Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer.
|NRG-GY006: A Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer.
|OVAL 3018: The OVAL Study" A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
|NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]||Danbury/Norwalk|
|Pancreas||15-10: The Role of MicroRNAs in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
|16-15: Pre- and Post-Surgical Molecular Testing in Individuals with Operable Pancreatic Cancer
|16-17: A Pancreatic Cancer Screening Study in High Risk Individuals
|18-01: A Pancreatic Cancer Screening Study in High Risk Individuals Including those with Recent-Onset Diabetes Mellitus
|A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer
|S2001: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations||Norwalk/Danbury|
|Colon||NRG-GI004/S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer||Danbury|
|NRG-GI005: Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer (COBRA)||Norwalk/Danbury|
|Prostate||C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
|Melanoma||SPY-X: A Study to Assess the Feasibility of Using Real-Time Fluorscence Lymphangiography Alone for Sentinel Node Localization in Patients with Melanoma or Breast Cancer
|Pisces KeyNote-695: A Multicenter Phase II, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment||VBMC|
|Neuroendocrine||A021602: Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on prior therapy (CABINET)||Norwalk/Danbury|
||15-35: Serum-based Signature of Activation of the PD-1/PD-L1 Pathway in Patients with Cancer. Serial serum samples from patients starting immune-based therapies that target the PD-1/PDL-1 pathway in cancer patients.
|BB001: The Western Connecticut Health Network (WCHN), Danbury and Norwalk Hospitals Biobank - A Collection of Biospecimens and Clinical Data to Facilitate Research (GYN Biobank)
|15-101: Enumeration of circulating plasma cells in MGUS and Multiple Myeloma
|IMPACT:12-245: Genomic Profiling in Cancer Patients
|City of Hope: Molecular Genetics Studies of Cancer Patients and Their Relatives||VBMC|
|Advanced Cancer_Anorexia||C3651010: A 6-Week, Randomized, Double-Blind, Sponsor-Open Study to assess the effect of repeated subcutaneous administration of PF-06946860 on Appetite in participants with Advanced Cancer and Anorexia, followed by an 18-week-Open-Label Treatment Period.||Norwalk/Danbury|
||C2321001: A Phase I dose escalation and expanded cohort study of PF-06821497 in the treatment of adult patients with Relapsed/refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and follicular lymphoma||Norwalk|
|AMG 510 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
|C3441037: A Phase 1, Open Label, Crossover Study to establish Bioequivalence between the proposed Soft Gel TALAZOPARIB Capsule Formulation AND the Current TALAZOPARIB Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed TALAZOPARIB Soft Gel Capsule Formulation in Participants with Adavnced Solid Tumors.